Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
Ascletis Inc., a Chinese biotech specializing in liver disease treatments with a focus on hepatitis C, has completed a major $100m Series B financing, following a first round $55m fundraising in the second half of 2015.
The second round was led by C-Bridge Capital, joined by a number of new investors including QianHai Equity Investment FOF,...
Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.
Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
